(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
概要:(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid(CAS 163562-63-8)是一种化学化合物,分子式为C23H36O12,分子量为504.22 g/mol。河南科弘生物科技有限公司提供CRO/CDMO定制合成服务,支持克级到吨级规格。
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
又称:(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid, (2S,3S,4S,5R,6R)-6-{[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid, [(3R,5S,5aR,6R,8aS,9R,10S,12R,12aS)-10-Ethoxydecahydro-3,6,9-trimethyl-3,12-epoxypyrano[4,3-j]-1,2-benzodioxepin-5-yl]beta-D-glucopyranosiduronic acid, [[(3R,5aalpha,8aalpha,12aS)-Decahydro-10beta-ethoxy-3,6alpha,9beta-trimethyl-3,12alpha-epoxypyrano[4,3-j]-1,2-benzodioxepin]-5alpha-yl]beta-D-glucopyranosiduronic acid
| 分子式 | C23H36O12 |
|---|---|
| 分子量 | 504.22 g/mol |
| LogP | 0.1182 |
| 拓扑极性表面积 | 162.6 Ų |
| 氢键供体数 | 4 |
| 氢键受体数 | 11 |
| 可旋转键数 | 5 |
| 精确质量 | 504.22067 |
| 重原子数 | 35 |
| 复杂度 | 811.3712 |
化学标识符
| CAS 编号 | 163562-63-8 |
|---|---|
| SMILES | CCO[C@@H]1[C@@H]([C@@H]2CC[C@H]([C@H]3[C@]24[C@H](O1)O[C@@](C[C@@H]3O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)(OO4)C)C)C |
产品概述
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid(CAS 163562-63-8),分子式为C23H36O12,分子量为504.22 g/mol。IUPAC名:(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid。
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid化学性质概览
属性洞察:(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的XLogP值为0.1182,表明具有中等亲脂性,在水溶性和膜透过性之间取得平衡。 TPSA为162.6 Ų,极性较高,提示该化合物膜透过性可能受限但水溶性较好。 根据Lipinski五规则,(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid有4个氢键供体和11个氢键受体,可能需要考虑配方优化。
常见问题
常见问题
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的CAS号是多少?
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的CAS号为163562-63-8。
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的分子式是什么?
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的分子式为C23H36O12。
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的分子量是多少?
(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的分子量为504.22 g/mol。
在哪里可以购买(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid?
您可以直接向科弘生物询价(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid。联系我们或发送邮件至info@kehongbio.com获取报价和库存信息。
科弘生物是否提供(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid的定制合成服务?
是的,科弘生物提供(2S,3S,4S,5R,6R)-6-[[(1R,3S,4R,5R,8S,9R,10S,12R,13S)-10-Ethoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid及相关化合物的定制合成服务。请联系我们并告知您的具体需求,包括数量、纯度和交期。